CLY-124 is a Globin-Switching oral therapeutic designed to treat SCD by increasing fetal hemoglobin (HbF) via a non-cytotoxic mechanism of action. It was discovered from Cellarity’s proprietary drug discovery platform, through which single-cell transcriptomics mapping and dynamic AI modeling revealed an undiscovered target controlling the Globin-Switching mechanism – naturally increasing HbF to reduce the burden of the disease.
